Related Experiment Videos
High intravenous phenytoin dosage requirement in a newborn infant
Insights
This study highlights the challenges in managing neonatal seizures with phenytoin. Increased dosing and frequent monitoring are crucial due to rapid changes in phenytoin metabolism in newborns.
Area of Science:
- Neonatal pharmacology
- Clinical pharmacokinetics
Background:
- Intravenous phenytoin is used for neonatal seizures.
- Therapeutic drug monitoring is essential for effective treatment.
Observation:
- A term neonate required high-dose phenytoin (25 mg/kg/day) with frequent dosing intervals (6 hours).
- Phenytoin serum levels declined significantly between postnatal days 8-13, indicating increased metabolism.
- Rapid elimination was confirmed with a half-life of 8.8 hours by day 18.
Findings:
- Phenytoin pharmacokinetics in neonates are dynamic and can change rapidly.
- Maturing oxidative metabolism and concurrent phenobarbital administration likely contributed to increased phenytoin elimination.
- A constant dose of 9 mg/kg/day was insufficient to maintain therapeutic levels.
Implications:
- Neonatal phenytoin dosing requires individualized adjustments based on frequent serum concentration monitoring.
- Increased loading doses and maintenance doses may be necessary to manage neonatal seizures effectively.
- Understanding changing pharmacokinetics is vital to balance efficacy and minimize toxicity risks in neonates.
Abstract:
A term neonate was being treated with intravenous phenytoin. To maintain a serum level above 10 micrograms per milliliter and abolish seizure activity, it was necessary to carry out repeated serum concentration measurements, administer several loading doses, and administer an unusually large maintenance dose (25 mg per kilogram per day), divided into a short dosing interval (6 hours). Declining serum levels from postnatal days 8 to 13 on a constant dose of 9 mg per kilogram per day suggested that the rate of phenytoin metabolism was gradually increasing; rapid elimination was documented on day 18 by a half-life measurement of 8.8 hours from three samples. The changing pharmacokinetics were attributed to maturation of oxidative metabolism of phenytoin, concurrent phenobarbital administration, or both. The need for additional loading doses and maintenance dose increases must be guided by serum concentration measurements to obtain maximum benefit with minimal risk of toxicity.